Basics Amicus Therapeutics, Inc. Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines. IPO Date: May 31, 2007 Sector: Healthcare Industry: Biotech Market Cap: $1.9B Activated in VL: True Average Daily Range Avg Daily Range: $0.24 | 2.67% Avg Daily Range (30 D): $0.13 | 1.98% Avg Daily Range (90 D): $0.13 | 1.77% Institutional Daily Volume Avg Daily Volume: 1.47M Avg Daily Volume (30 D): 4.31M Avg Daily Volume (90 D): 3.06M Trade Size Avg Trade Size (Sh.): 147 Avg Trade Size (Sh.) (30 D): 155 Avg Trade Size (Sh.) (90 D): 129 Institutional Trades Total Inst.Trades: 7,194 Avg Inst. Trade: $2.89M Avg Inst. Trade (30 D): $3.14M Avg Inst. Trade (90 D): $2.7M Avg Inst. Trade Volume: .25M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.57M Avg Closing Trade (30 D): $4.34M Avg Closing Trade (90 D): $3.77M Avg Closing Volume: 315.49K     News Jun 3, 2025 @ 11:00 AM New Analysis of Pombiliti® (cipaglucosidase alf... Source: Amicus Therapeutics May 30, 2025 @ 11:00 AM Amicus Therapeutics to Present at Upcoming Investo... Source: N/A Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Feb 10, 2025 @ 12:00 PM Amicus Therapeutics to Announce Full-Year 2024 Fin... Source: N/A Feb 3, 2025 @ 12:00 PM Amicus Therapeutics Announces Presentations and Po... Source: N/A Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.07 $-.02 Diluted EPS $-.07 $-.02 Revenue $ $ 125.25M $ 141.52M Gross Profit $ $ 113.55M $ 128.24M Net Income / Loss $ $ -21.69M $ -6.73M Operating Income / Loss $ $ -7.95M $ 21.66M Cost of Revenue $ $ 11.7M $ 13.28M Net Cash Flow $ $ -31.98M $ 24.46M PE Ratio